Berkeley Capital Partners’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.51M | Buy |
9,899
+7,515
| +315% | +$1.15M | 0.35% | 61 |
|
|
2025
Q4 | $329K | Buy |
2,384
+317
| +15% | +$41.5K | 0.08% | 155 |
|
|
2025
Q3 | $265K | Buy |
2,067
+140
| +7% | +$17.1K | 0.06% | 155 |
|
|
2025
Q2 | $233K | Sell |
1,927
-350
| -15% | -$39.4K | 0.06% | 157 |
|
|
2025
Q1 | $254K | Sell |
2,277
-131
| -5% | -$13.9K | 0.07% | 150 |
|
|
2024
Q4 | $234K | Sell |
2,408
-3,608
| -60% | -$385K | 0.07% | 157 |
|
|
2024
Q3 | $692K | Sell |
6,016
-12,188
| -67% | -$1.38M | 0.2% | 99 |
|
|
2024
Q2 | $1.94M | Buy |
18,204
+52
| +0.3% | +$5.22K | 0.58% | 29 |
|
|
2024
Q1 | $1.76M | Buy |
18,152
+11,893
| +190% | +$1.22M | 0.54% | 34 |
|
|
2023
Q4 | $632K | Sell |
6,259
-178
| -3% | -$17.2K | 0.21% | 93 |
|
|
2023
Q3 | $656K | Sell |
6,437
-259
| -4% | -$26.3K | 0.24% | 81 |
|
|
2023
Q2 | $676K | Sell |
6,696
-9,857
| -60% | -$986K | 0.24% | 81 |
|
|
2023
Q1 | $1.52M | Buy |
16,553
+231
| +1% | +$20.2K | 0.56% | 33 |
|
|
2022
Q4 | $1.48M | Buy |
16,322
+700
| +4% | +$59K | 0.57% | 33 |
|
|
2022
Q3 | $1.19M | Buy |
15,622
+1,535
| +11% | +$127K | 0.51% | 35 |
|
|
2022
Q2 | $1.19M | Buy |
14,087
+1,530
| +12% | +$134K | 0.49% | 34 |
|
|
2022
Q1 | $1.1M | Buy |
12,557
+8,713
| +227% | +$754K | 0.44% | 36 |
|
|
2021
Q4 | $336K | Buy |
3,844
+981
| +34% | +$81.5K | 0.14% | 102 |
|
|
2021
Q3 | $234K | Buy |
2,863
+65
| +2% | +$5.85K | 0.11% | 124 |
|
|
2021
Q2 | $255K | Sell |
2,798
-168
| -6% | -$15K | 0.11% | 118 |
|
|
2021
Q1 | $254K | Buy |
2,966
+143
| +5% | +$12.8K | 0.12% | 106 |
|
|
2020
Q4 | $267K | Buy |
2,823
+25
| +0.9% | +$2.19K | 0.14% | 98 |
|
|
2020
Q3 | $243K | Sell |
2,798
-126
| -4% | -$10.9K | 0.15% | 92 |
|
|
2020
Q2 | $255K | Sell |
2,924
-103
| -3% | -$8.89K | 0.16% | 90 |
|
|
2020
Q1 | $250K | Sell |
3,027
-250
| -8% | -$22.3K | 0.17% | 98 |
|
|
2019
Q4 | $310K | Sell |
3,277
-27
| -0.8% | -$2.42K | 0.16% | 106 |
|
|
2019
Q3 | $287K | Sell |
3,304
-124
| -4% | -$11.1K | 0.15% | 113 |
|
|
2019
Q2 | $313K | Sell |
3,428
-426
| -11% | -$36.1K | 0.15% | 111 |
|
|
2019
Q1 | $332K | Buy |
3,854
+118
| +3% | +$9.47K | 0.16% | 104 |
|
|
2018
Q4 | $287K | Buy |
3,736
+67
| +2% | +$5.21K | 0.16% | 106 |
|
|
2018
Q3 | $283K | Buy |
+3,669
| New | +$271K | 0.16% | 103 |
|
|
2017
Q4 | – | Sell |
-2,974
| Closed | -$229K | – | 122 |
|
|
2017
Q3 | $229K | Sell |
2,974
-4,353
| -59% | -$329K | 0.15% | 112 |
|
|
2017
Q2 | $548K | Buy |
+7,327
| New | +$519K | 0.37% | 68 |
|
Other funds holding NVS
Berkeley Capital Partners's NVS Position: Q1 2026 in Review
Berkeley Capital Partners increased its Novartis (NVS) stake by 315% in Q1 2026, buying an estimated $1.15M and bringing the position to 9,899 shares worth $1.51M. The position accounts for 0.35% of the portfolio, ranked #61.
Berkeley Capital Partners first reported a position in NVS in Q2 2017 and has held it in 33 quarters since. The position peaked at $1.94M in Q2 2024. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Berkeley Capital Partners held 9,899 shares of Novartis worth $1.51M as of Q1 2026.
- Berkeley Capital Partners bought 7,515 Novartis shares in Q1 2026, an estimated $1.15M.
- Novartis made up 0.35% of Berkeley Capital Partners's portfolio in Q1 2026, its #61 holding.
- Berkeley Capital Partners first reported a position in Novartis in Q2 2017 and has held it in 33 quarters since.
- Berkeley Capital Partners's Novartis position peaked at $1.94M in Q2 2024.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Berkeley Capital Partners's 13F filing for Q1 2026, filed 7 May 2026.